Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2022-12-19 Board/Management Inform…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Valberedning utsedd inför BioInvent Internationals årsstämma 2023
Board/Management Information Classification · 99% confidence The document text is a short announcement (2674 characters) dated December 19, 2022, regarding the appointment of the Nomination Committee (Valberedning) members for the upcoming Annual General Meeting (Årsstämma) in 2023. It details who the members are and what they will propose (e.g., board composition, remuneration). The key phrase is the title and content focusing on the 'Valberedning' (Nomination Committee) and 'årsstämma' (AGM). This content directly relates to the preparation and governance surrounding the Annual General Meeting. While it is an announcement, the subject matter is highly specific to AGM procedures, making 'AGM Information' (AGM-R) the most appropriate classification over a general 'Report Publication Announcement' (RPA) or 'Regulatory Filing' (RNS), as it provides substantive information about the AGM process itself, not just the publication of a report.
2022-12-19 Swedish
Earnings Release 2022
Earnings Release Classification · 99% confidence The document provides detailed financial highlights for the third quarter (Q3) of 2022, including Net Sales, Net Income, and Cash Flow, along with year-to-date figures. It also details significant operational events during the quarter, such as a directed new share issue (financing activity), board changes, and clinical trial progress updates (drug development). The structure, content (financial metrics for a specific period), and the mention of 'Tredje kvartalet 2022' strongly indicate this is a comprehensive report covering a period shorter than a year. This aligns perfectly with the definition of an Interim/Quarterly Report (IR). It is not just an Earnings Release (ER) because it contains extensive operational and pipeline details beyond just the key financial highlights, and it is not a 10-K as it covers only Q3. 9M 2022
2022-10-27 Swedish
Earnings Release 2022
Earnings Release Classification · 99% confidence The document provides a detailed financial summary for the 'Third quarter 2022' and 'January – September 2022', including key metrics like Net sales, Profit/loss after tax, and Cash flow. It also discusses clinical trial progress and corporate events (like a share issue). This structure, focusing on period-specific financial results and operational highlights, is characteristic of a comprehensive report covering a period shorter than a full year. Since it covers Q3 and YTD 2022, it fits the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains extensive financial tables and management commentary, nor is it the full Annual Report (10-K). 9M 2022
2022-10-27 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim report for BioInvent International AB covering the second quarter and the first half of 2022. It contains detailed financial statements (net sales, profit/loss, cash flow, and balance sheet items), management's discussion and analysis (MDA) of business trends, clinical trial progress, and corporate updates. It is not a mere announcement (RPA) or a simple earnings release (ER), as it provides extensive narrative and financial data. Therefore, it is classified as an Interim/Quarterly Report. Q2 2022
2022-08-25 Swedish
Investor Presentation 2022
Investor Presentation Classification · 99% confidence The document provides a detailed financial summary for the 'Second quarter 2022' and 'January – June 2022', including key metrics like Net sales, Profit after tax, and Cash flow. It also discusses clinical progress, licensing deals, financing activities (directed share issue in July), and leadership changes. The text explicitly states: "This information is information as BioInvent International AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication... on August 25, 2022." This structure—quarterly financial highlights combined with operational updates, released on a specific date—is characteristic of an Interim/Quarterly Report. Since it covers the first half of the year (January-June) and the second quarter, it is not the Annual Report (10-K). It is more comprehensive than a simple Earnings Release (ER) which usually contains only highlights. Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2022-08-25 English
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement dated July 29, 2022, titled "Ändring av antalet aktier och röster i BioInvent International AB" (Change in the number of shares and votes in BioInvent International AB). It explicitly states the new total number of shares (64,967,884) and attributes the increase to a directed share issue (emission) that was previously announced. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. Although it mentions a previous financing event, the core content is the final notification of the resulting share count change.
2022-07-29 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.